Mepolizumab For The Treatment Of Patients With Eosinophilic Granulomatosis With Polyangiitis: A Phase Iii Randomized, Placebo-Controlled Trial

Ítems similars

• Mepolizumab or placebo for eosinophilic granulomatosis with polyangiitis
  per: Wechsler, M, et al.
  Publicat: (2017)
• OP0130 Mepolizumab for the treatment of patients with eosinophilic granulomatosis with polyangiitis: a phase iii randomised, placebo-controlled trial
  per: Wechsler, M, et al.
  Publicat: (2017)
• Clinical Benefit of Mepolizumab in Eosinophilic Granulomatosis With Polyangiitis for Patients With and Without a Vasculitic Phenotype
  per: Benjamin Terrier, et al.
  Publicat: (2023-07-01)
• Safety and Efficacy of Mepolizumab in Patients with Eosinophilic Granulomatosis with Polyangiitis
  per: Ravi Ranjan Pradhan, et al.
  Publicat: (2019-01-01)
• Real-life efficacy and safety of mepolizumab for eosinophilic granulomatosis with polyangiitis
  per: Giuseppe A. Ramirez, et al.
  Publicat: (2022-12-01)